PGT-A (Preimplantation Genetic Testing for Aneuploidy)

PGT-A involves biopsying several cells from the trophectoderm of a blastocyst, then analyzing the DNA for gains or losses of chromosomes (aneuploidy). Euploid embryos (46 chromosomes) are more likely to implant and less likely to miscarry than untested embryos.

PGT-A is most commonly offered to women of advanced maternal age (over 35–37), couples with recurrent pregnancy loss, and those with repeated implantation failure. While PGT-A increases the chance of success per transfer and reduces miscarriage rates, it requires viable blastocysts to biopsy and adds cost (typically $3,000–$6,000). Some embryos with abnormal PGT-A results are mosaic and may still lead to healthy babies, so results require nuanced counseling.